Related Experiment Videos
Hemodynamic and counterregulatory effects of calcium antagonists in hypertension
1Department of Medicine, University Hospital, Kantosspital Basel, Switzerland.
Insights
Calcium antagonists effectively lower high blood pressure by reducing systemic vascular resistance. These drugs offer a favorable hemodynamic profile, making them valuable for essential hypertension monotherapy.
Area of Science:
- Cardiovascular Pharmacology
- Hypertension Management
Background:
- Essential hypertension is characterized by increased systemic vascular resistance, driven by elevated calcium influx.
- Calcium antagonists reduce cytosolic free calcium, primarily by inhibiting transmembraneous calcium influx, acting as potent arterial vasodilators.
Purpose of the Study:
- To evaluate the hemodynamic and neurohumoral effects of calcium antagonists in managing essential hypertension.
- To compare the efficacy and side effect profiles of different classes of calcium antagonists.
Main Methods:
- Review of pharmacological actions of calcium antagonists on vascular resistance and blood pressure.
- Analysis of effects on cytosolic calcium, sympathetic nervous system activity, and the renin-angiotensin-aldosterone system.
- Comparison of dihydropyridine, verapamil, and diltiazem types regarding vasodilatory potency and inotropic effects.
Main Results:
- Calcium antagonists lower blood pressure by reducing systemic vascular resistance without significant sympathetic activation or volume retention.
- Dihydropyridine calcium antagonists exhibit greater arterial vasodilatation potency compared to verapamil or diltiazem, with fewer negative inotropic effects.
- Improved intrarenal hemodynamics and diuretic effects contribute to the absence of volume retention.
Conclusions:
- Calcium antagonists possess a favorable hemodynamic and neurohumoral profile for hypertension treatment.
- Their proven efficacy and safety profile make them a valuable option for monotherapy in essential hypertension.
- While all calcium antagonists are effective, dihydropyridines may offer enhanced vasodilatory benefits.
Abstract:
Increased systemic vascular resistance in essential hypertension depends on increased calcium influx. Calcium antagonists lower cytosolic free calcium concentrations mainly through a reduction of transmembraneous calcium influx and are potent arterial vasodilators. Dihydropyridine calcium antagonists are pharmacologically more potent with respect to arterial vasodilatation than verapamil- or diltiazem-type calcium antagonists and have less or no clinically detectable negative inotropic effects, but this seems to be of importance only in patients with reduced cardiac function. All calcium antagonists lower high blood pressure through a reduction of elevated systemic vascular resistance without clinically relevant activation of sympathetic reflexes or the renin-angiotensin-aldosteron system. However, subtle changes of sympathetic nervous system activity may codetermine the acute and chronic blood pressure response. They do not lead to volume retention because of improved intrarenal hemodynamics and a diuretic effect. Interference with angiotensin and sympathetically mediated vasoconstrictor mechanisms probably also contributes to their antihypertensive effect. This hemodynamic profile is similar for all calcium antagonists but the degree of acute sympathetic stimulation seems to be greater for dihydropyridines. Their overall favorable hemodynamic and neurohumoral profile and their proven efficacy and lack of serious side effects have made calcium antagonists a valuable addition to the armanentarium available for monotherapy of hypertension.